

GUIDE FOR PATIENTS WITH CIDP



gamunex-c
immune globulin injection (human), 10%
caprylate/chromatography purified

**Step out of the
symptoms of CIDP
and back into your
life with GAMUNEX-C**

Hypothetical patient for
illustrative purposes only.

CIDP, chronic inflammatory demyelinating polyneuropathy.

**Please see Important Safety Information on pages 12-13 and
refer to accompanying full [Prescribing Information](#) for GAMUNEX-C.**


GRIFOLS

What is CIDP?

CIDP is a rare, typically progressive autoimmune disease that involves nerve damage or dysfunction in the arms and legs. It occurs when the immune system malfunctions, creating an inflammatory response. The immune system attacks the peripheral nerves, which are nerves located outside the brain and spinal cord.^{1,2}

In CIDP, the autoimmune process damages the protective covering of the nerves, called the myelin sheath. This impairs the ability of nerve fibers to carry signals between the brain and various parts of the body.^{1,2}

Starting treatment for CIDP as soon as possible can help protect the nerves from damage.^{3,4}



CIDP, chronic inflammatory demyelinating polyneuropathy.

**Please see Important Safety Information
on pages 12-13 and refer to accompanying
full [Prescribing Information](#)
for GAMUNEX-C.**

What are common symptoms of CIDP?

CIDP symptoms can vary from person to person and usually occur on both sides of the body at the same time. Symptoms of CIDP may appear in the arms and legs. The most common CIDP symptoms are⁵⁻⁹:

- Loss of muscle strength
- Change in sensation in the feet, fingers, and hands

The symptoms of CIDP, such as numbness, tingling, weakness, and balance issues, can make daily activities a challenge. Reaching for items, climbing stairs, or walking may be difficult. Fatigue and pain may occur, which can be frustrating and even debilitating.^{8,9}

CAREGIVER TIP

If you care for someone with CIDP, you may hear them describe their symptoms as...

“a lightning storm taking place in my arms and legs.”



CIDP, chronic inflammatory demyelinating polyneuropathy.

Please see Important Safety Information on pages 12-13 and refer to accompanying full [Prescribing Information](#) for GAMUNEX-C.

What is GAMUNEX-C?

GAMUNEX-C is an immune globulin, or IG, therapy for the treatment of adult patients with CIDP.¹⁰

IG is a medicine made from proteins called antibodies that are taken from human plasma, the liquid part of the blood.^{11,12}



GAMUNEX-C may work in multiple ways to fight the autoimmune and inflammatory processes in CIDP.¹³



Treatment with GAMUNEX-C is proven to improve symptoms and protect the nerves.^{14,15}



Not actual sizes.

The way in which GAMUNEX-C works in the treatment of people with CIDP is not completely understood.¹⁰

Do not take GAMUNEX-C if you have an allergy to immune globulin. Tell your doctor if you have had a serious reaction to other medicines that contain immune globulin. Also, tell your doctor if you have immunoglobulin A (IgA) deficiency. If you have a serious reaction while taking GAMUNEX-C, stop taking it immediately and tell your doctor.¹⁰

CIDP, chronic inflammatory demyelinating polyneuropathy.

Please see Important Safety Information on pages 12-13 and refer to accompanying full [Prescribing Information](#) for GAMUNEX-C.

Hypothetical patient for
illustrative purposes only.

gamunex-c
immune globulin injection (human), 10%
caprylate/chromatography purified



#1

**#1-prescribed IG
treatment for CIDP¹⁶**

IG, immune globulin; CIDP, chronic inflammatory demyelinating polyneuropathy.

**Please see Important Safety Information
on pages 12-13 and refer to accompanying
full [Prescribing Information](#)
for GAMUNEX-C.**



Will GAMUNEX-C work for me?



A landmark clinical trial demonstrated that GAMUNEX-C was effective for both short-term and long-term treatment of most patients with CIDP. Among the patients who responded to GAMUNEX-C in a clinical study, some patients started to improve by week 3, and most started to improve by week 6.^{14,15}

The study demonstrated that a majority of patients who received GAMUNEX-C had:

- Significant improvement in disability scores through week 24¹⁵
- Improved grip strength in both hands¹⁴
- Improved physical, emotional, and social functioning¹⁷

For responders who received GAMUNEX-C every 3 weeks for 48 weeks, 87.1% were relapse-free, compared with 57.7% of people who received placebo.¹⁴

In a clinical study of patients with CIDP who received GAMUNEX-C intravenously, the most common side effects were pain in the region of the head or neck; raised body temperature or fever; abnormally high blood pressure; feelings of coldness accompanied by shivering; a noticeable change in the skin's texture or color such as scaliness, bumps, itching, or other irritation; a sensation of unease and discomfort in the upper stomach; joint pain; and abnormal physical weakness or lack of energy.¹⁰

The most serious side effect in a CIDP clinical trial was a blood clot to the lung (pulmonary embolism) in 1 patient with a history of this condition.¹⁰

The way in which GAMUNEX-C works in the treatment of people with CIDP is not completely understood.¹⁰

CIDP, chronic inflammatory demyelinating polyneuropathy.

Please see Important Safety Information on pages 12-13 and refer to accompanying full [Prescribing Information](#) for GAMUNEX-C.

What about my personal goals for CIDP treatment?

Treatment for CIDP includes short- and long-term goals that you and your healthcare team decide on together. Talking about your personal goals with your healthcare team can help guide decisions about your treatment. Some possible goals could be:

Short-term goals

- Feeling better: your symptoms and quality of life improve
- Understanding your diagnosis and what treatment will involve

Long-term goals

- Regaining and maintaining your functionality and independence
- Recognizing and addressing other quality-of-life concerns you may have
- Reducing the physical, emotional, and mental burdens of treatment

Hypothetical patient for illustrative purposes only.



CIDP, chronic inflammatory demyelinating polyneuropathy.

Please see Important Safety Information on pages 12-13 and refer to accompanying full [Prescribing Information](#) for GAMUNEX-C.

How is GAMUNEX-C administered?

For treatment of CIDP, GAMUNEX-C is administered intravenously (IV) through a vein, typically in the arm.¹⁰

The first infusion may be split up over several days. Subsequent infusions usually last 2-4 hours from start to finish.¹⁰

GAMUNEX-C can be given in the home, a hospital, or an infusion center by a healthcare professional.¹⁸

For ongoing treatment of CIDP, GAMUNEX-C requires just 1 needle site, 1 infusion, once every 3 weeks.¹⁰

**Your doctor or infusion nurse
may ask you to keep track of how
you're feeling to help evaluate
your response to therapy.**



Scan to view a video
of how GAMUNEX-C
is administered or
visit [GAMUNEX-C.com](https://www.gamunex-c.com).

CIDP, chronic inflammatory demyelinating polyneuropathy.

**Please see Important Safety Information
on pages 12-13 and refer to accompanying
full [Prescribing Information](#)
for GAMUNEX-C.**

What are the possible side effects?

Talk with your healthcare team about possible side effects and what to expect.

In a clinical study, the most common side effects in patients with CIDP who received GAMUNEX-C were¹⁰:

- Pain in the region of the head or neck
- Raised body temperature or fever
- Abnormally high blood pressure
- Feelings of coldness and/or shivering
- Noticeable change in the skin's texture or color, such as scaliness, bumps, itching, or other irritation
- Sensation of unease and discomfort in the upper stomach
- Joint pain
- Abnormal physical weakness or lack of energy

Although very rare, treatment with GAMUNEX-C may cause serious side effects, such as blood clots in the lungs (pulmonary embolism).¹⁰

**Have questions or concerns
about potential side effects?
Talk with your healthcare team
to learn what to look for.**



CIDP, chronic inflammatory demyelinating polyneuropathy.

**Please see Important Safety Information
on pages 12-13 and refer to accompanying
full [Prescribing Information](#)
for GAMUNEX-C.**



Gamunex Connexions is a patient support program that provides financial assistance for eligible patients, educational resources, and help with questions about therapy.

Gamunex Connexions offers financial support programs to help with medication costs for eligible patients

COPAY ASSISTANCE PROGRAM

- For eligible patients* with commercial or private insurance, copay assistance of up to \$10,000 per calendar year is available to help with copayments, coinsurance, and deductibles.

PATIENT ASSISTANCE PROGRAM (PAP)

- For eligible patients without insurance, the Patient Assistance Program provides medication free of charge.

*Subject to terms and conditions. For more information, visit GAMUNEX-C.com.

Enrollment is simple—you can enroll online at: www.connexions.grifols.com or by printing an enrollment form from our website. Once you complete filling out the form, email to grifolsconnexions@cardinalhealth.com, or fax to 1-877-375-0758.

**Call the Gamunex Connexions team at
1-888-MYGAMUNEX (1-888-694-2686)
for support and financial needs.**

Monday through Friday (8 AM to 8 PM ET)



**Please see Important Safety Information
on pages 12-13 and refer to accompanying
full [Prescribing Information](#)
for GAMUNEX-C.**

“It was very positive for us to learn that GAMUNEX-C has a patient support program.”

— BUD, a real patient with CIDP



Sign up on GAMUNEX-C.com to receive more information about GAMUNEX-C.

CIDP, chronic inflammatory demyelinating polyneuropathy.

Please see Important Safety Information on pages 12-13 and refer to accompanying full [Prescribing Information](#) for GAMUNEX-C.

IMPORTANT SAFETY INFORMATION

GAMUNEX[®]-C (immune globulin injection [human], 10% caprylate/chromatography purified) is approved to treat primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older. If you have PIDD, you may take GAMUNEX-C under the skin (subcutaneously) or in a vein (intravenously). GAMUNEX-C is also approved to treat idiopathic thrombocytopenic purpura (ITP) in adults and children and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. If you have ITP or CIDP, you may only take GAMUNEX-C intravenously.

If you take GAMUNEX-C or a similar immune globulin product, you could experience a serious and life-threatening blood clot (thromboembolism), which may include pain and/or swelling of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, numbness, or weakness on one side of the body. You are more likely to develop a blood clot if you have a history of hardening of the arteries (atherosclerosis), stroke, heart attack, or heart failure (low volume of blood pumped by the heart). You may also be more likely to get a blood clot if you are elderly, if you have a blood clotting disorder, if you are inactive for long periods of time (such as long bed rest), if you use estrogens, or if you have thickening of your blood. For patients at risk, GAMUNEX-C should be administered at the lowest dose and slowest infusion rate that is practical. However, blood clots may occur in the absence of any of the known risk factors. Patients should be well hydrated by drinking enough water before GAMUNEX-C is administered. Tell your doctor immediately if your medical history is similar to what is described here, and especially if you start having any of these symptoms while taking GAMUNEX-C.

If you take GAMUNEX-C or a similar immune globulin product intravenously, you could experience serious kidney disease and death. You may have symptoms of decreased urination, sudden weight gain, swelling in your legs (edema), or shortness of breath. You are more likely to develop serious kidney disease if you already have a kidney problem, have Type II diabetes mellitus, or are older than 65. You are more likely to develop serious kidney disease if you are dehydrated, have a blood infection (sepsis), have high protein content in your blood, or if you are receiving other medicines that are harmful to your kidneys. Tell your doctor immediately if your medical history is similar to what is described here, and especially if you start having any of these symptoms while taking GAMUNEX-C.

You are more likely to develop serious kidney disease if you take an intravenous immune globulin product that contains sugar (sucrose). GAMUNEX-C does not contain sugar. If your situation makes you more likely to experience serious kidney disease, you should take GAMUNEX-C at the lowest concentration available and the slowest infusion rate that is practical.

Do not take GAMUNEX-C if you have an allergy to immune globulin. Tell your doctor if you have had a serious reaction to other medicines that contain human immune globulin. Also tell your doctor if you have immunoglobulin A (IgA) deficiency. If you have a serious reaction while taking GAMUNEX-C, stop taking it immediately and tell your doctor.

Periodic monitoring of kidney function and urine output is particularly important in patients more likely to experience severe kidney disease.

You could experience other serious and life-threatening problems due to immune globulin. You could get aseptic meningitis (a type of brain inflammation with symptoms of severe headache, stiff neck, fatigue, fever, sensitivity to light, painful eye movements, nausea, and vomiting), a blood problem called hemolytic anemia (common symptoms include increased heart rate, fatigue, yellow skin or eyes, and dark-colored urine), and/or a lung problem called transfusion-related acute lung injury (commonly referred to as TRALI).

Please refer to accompanying full [Prescribing Information](#) for GAMUNEX-C.

IMPORTANT SAFETY INFORMATION (cont.)

TRALI is a condition where you build up fluid in the lungs (called pulmonary edema) that is not the result of heart failure.

If you have higher than normal body fluid volumes or if you have a condition where increasing body fluid volume may be a concern, a higher dose, such as 1g/kg for 1-2 days, is not recommended.

Because GAMUNEX-C is made from human blood, it may carry a risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

You may not take GAMUNEX-C subcutaneously if you have ITP. **If you have ITP and take GAMUNEX-C subcutaneously, you could experience a very serious and life-threatening black and blue wound (hematoma, which is a pocket of blood within a tissue).**

After you take GAMUNEX-C, your blood antibody levels may rise, which could cause some blood antibody tests to give false results.

The most common side effects in a clinical study with PIDD patients who got subcutaneous injections of GAMUNEX-C were infusion-site reactions such as redness, swelling, and itching; extreme tiredness; pain in the region of the head or neck; a runny nose, nasal congestion, sneezing, cough, and sputum production; joint pain; loose stools; a sensation of unease and discomfort in the upper stomach; swelling of the tissue lining the sinuses; inflammation of the airways that carry air to your lungs; a feeling of unhappiness, sadness, melancholy, gloom, hopelessness, or low spirits; red rash or bumps, itchy, swollen, and tender skin with or without blisters or a burning feeling; a severe throbbing pain or a pulsing sensation, usually on just one side of the head; muscle pain; familiar infectious diseases such as the common cold or flu; and raised body temperature or fever. In clinical studies with PIDD patients who got GAMUNEX-C intravenously, the most common side effects were cough; irritation and inflammation of the mucous membrane inside the nose; sore throat caused by inflammation of the back of the throat; pain in the region of the head or neck; a condition in which your airways narrow and swell and produce extra mucus; a sensation of unease and discomfort in the upper stomach; raised body temperature or fever; loose stools; and swelling of the tissue lining the sinuses. In a clinical study with CIDP patients who got GAMUNEX-C intravenously, the most common side effects were pain in the region of the head or neck; raised body temperature or fever; abnormally high blood pressure; feelings of coldness accompanied by shivering; a noticeable change in the texture or color of your skin such as your skin becoming scaly, bumpy, itchy, or otherwise irritated; a sensation of unease and discomfort in the upper stomach; joint pain; and abnormal physical weakness or lack of energy. In clinical trials with ITP patients who got GAMUNEX-C intravenously, the most common side effects were pain in the region of the head or neck; a discoloration of the skin resulting from bleeding underneath, typically caused by bruising; vomiting, fever, nausea, rash, abdominal pain, back pain, and a pain or an uncomfortable feeling in the upper middle part of your stomach.

The most serious side effects in clinical studies were a blood clot to the lung (pulmonary embolism) in 1 patient with a history of this condition (in CIDP), a flare-up of an existing type of anemia (autoimmune pure red cell aplasia) in 1 patient (in PIDD), and heart inflammation (myocarditis) in 1 patient (in ITP).

Please refer to accompanying full [Prescribing Information](#) for GAMUNEX-C.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

CIDP resources and support*

The CIDP advocacy organizations below are intended to connect you to additional educational resources about treatment.



GBS|CIDP FOUNDATION INTERNATIONAL

GBS|CIDP Foundation International provides support and assistance to patients with Guillain-Barré syndrome (GBS), CIDP, and Multifocal Motor Neuropathy (MMN), and their families.

www.gbs-cidp.org



THE FOUNDATION FOR PERIPHERAL NEUROPATHY

The Foundation for Peripheral Neuropathy is the leading national nonprofit organization serving the peripheral neuropathy community.

www.foundationforpn.org

*These websites are provided as resources only and do not constitute an endorsement by Grifols of any particular content. Grifols does not review or control the content of non-Grifols websites.

CIDP, chronic inflammatory demyelinating polyneuropathy.

Please see Important Safety Information on pages 12-13 and refer to accompanying full [Prescribing Information](#) for GAMUNEX-C.



References: **1.** Dimachkie MM, Barohn RJ. Chronic inflammatory demyelinating polyneuropathy. *Curr Treat Options Neurol.* 2013;15(3):350-366. **2.** Peltier AC, Donofrio PD. Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside. *Semin Neurol.* 2012;32(3):187-195. **3.** Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. *N Engl J Med.* 2005;352(13):1343-1356. **4.** Allen JA, Gorson KC, Gelinas D. Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy. *Brain Behav.* 2018;8(3):e00932. **5.** Khoo A, Frasca J, Schultz D. Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. *Biomark Res.* 2019;7:3. **6.** Hughes R. Chronic inflammatory demyelinating polyradiculoneuropathy. *J Clin Immunol.* 2010;30(S1):70-73. **7.** Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. *Nat Rev Neurol.* 2011;7(9):507-517. **8.** CIDP. GBS/CIDP Foundation International website. Accessed August 12, 2026. <https://www.gbs-cidp.org/cidp> **9.** NORD® (National Organization of Rare Diseases). Chronic inflammatory demyelinating polyneuropathy. NORD website. Updated October 1, 2024. Accessed August 12, 2026. <https://rarediseases.org/rare-diseases/chronic-inflammatory-demyelinating-polyneuropathy> **10.** GAMUNEX-C Prescribing Information, Grifols. January 2020. **11.** National Institutes of Health. Understanding the immune system: how it works. US Department of Health and Human Services, National Institutes of Health; 2003. **12.** Premnath SM, Sankar P, Bassem K. Physiology, blood plasma. In: *StatPearls*. StatPearls Publishing; 2026. Updated July 15, 2026. Accessed August 12, 2026. <http://www.ncbi.nlm.nih.gov/books/NBK531504/> **13.** Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins – understanding properties and mechanisms. *Clin Exp Immunol.* 2009;158(suppl 1):2-13. **14.** Hughes RAC, Donofrio P, Bril V, et al; on behalf of the ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. *Lancet Neurol.* 2008;7(2):136-144. **15.** Latov N, Deng C, Dalakas MC, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. *Arch Neurol.* 2010;67(7):802-807. **16.** Data on file, Grifols. **17.** Merkies IS, Bril V, Dalakas MC, et al. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE study. *Neurology.* 2009;72(15):1337-1344. **18.** Jolles S, Orange JS, Gardulf A, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. *Clin Exp Immunol.* 2015;179(2):146-160.

**Please see Important Safety Information
on pages 12-13 and refer to accompanying
full [Prescribing Information](#)
for GAMUNEX-C.**



To learn more about **GAMUNEX-C**
and Gamunex Connexions,
visit GAMUNEX-C.com.

Please see Important Safety Information on pages 12-13 and
refer to accompanying full [Prescribing Information](#) for GAMUNEX-C.

GRIFOLS

© 2026 Grifols All rights reserved August 2026 US-GXC-2600145